Enrico Martin

213 Nerve reconstructions in extremity STS Methods Literature search A systematic search was performed in both PubMed and Embase databases according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, in order to identify all potentially relevant articles as of July 2018. A search string was built with the help of a professional librarian using search terms related to “soft tissue sarcoma” and “nerve reconstruction”. The exact search syntaxes for PubMed and Embase are shown in Supplementary Table 1 . All clinical studies evaluating outcomes after nerve reconstructions in extremity STS were included. All nerve transfers and nerve grafts were considered nerve reconstructions, unless an interposition graft was used to innervate a free functioning muscle transfer. Exclusion criteria included articles not stratifying outcomes for STS, no functional outcome measures presented, and STS not localized in extremities. The initial review was conducted by two independent authors (E.M. and M.J.D.). Disagreements were solved through discussion, in which one additional author was involved (J.H.C.). Data extraction and synthesis All data was extracted on individual patient level and included tumor grade (high/ low), tumor site, radio- and chemotherapy use, reconstruction(s) performed, oncologic and functional outcomes, and length of follow-up. Patients with bone sarcomas or non-extremity sites were excluded from qualitative synthesis, as well as patients with incomplete outcome data. Results were summarized and stratified by nerve reconstructed. Objective outcome measures scales included strength measured in weight-bearing, grasp power, grip/pinch strength and in the Medical Research Council muscle grade (MRC: M0-M5), range of motion, use of ambulatory devices, and sensation measured in the Medical Research Council sensory grade (MRCS: S0-S4) using two- point discrimination or with Semmes-Weinstein monofilament testing. Subjective outcome measures included the musculoskeletal tumor society scale (MSTS: 0-30), a visual acuity scale for pain (VAS: 0-10), and the disability of the arm, shoulder, and hand questionnaire (DASH: 0-100). 9